Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

BUY
$234.96 - $292.55 $2.67 Million - $3.33 Million
11,375 New
11,375 $3.21 Million
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $1.14 Million - $1.35 Million
-5,155 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $912,486 - $1.15 Million
5,155 New
5,155 $1.13 Million
Q4 2020

Feb 16, 2021

SELL
$207.01 - $276.09 $2.58 Million - $3.44 Million
-12,467 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$255.65 - $303.1 $2.71 Million - $3.22 Million
-10,613 Reduced 45.98%
12,467 $3.39 Million
Q2 2020

Aug 14, 2020

BUY
$225.48 - $295.8 $3.31 Million - $4.35 Million
14,699 Added 175.38%
23,080 $6.7 Million
Q1 2020

May 15, 2020

SELL
$199.77 - $247.81 $3.74 Million - $4.64 Million
-18,719 Reduced 69.07%
8,381 $1.99 Million
Q4 2019

Feb 14, 2020

BUY
$166.71 - $223.91 $4.52 Million - $6.07 Million
27,100 New
27,100 $5.93 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $133B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Cinctive Capital Management LP Portfolio

Follow Cinctive Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cinctive Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Cinctive Capital Management LP with notifications on news.